Back to Publications

Note: The following publications may contain information that is not consistent with the approved prescribing information for resmetirom. These publications do not constitute a recommendation for use outside of country-specific labeling.

Download all
  • EASL 2026 - Clinical
TitleDescriptionDownload
Baseline ANTICIPATE score and response predicts liver outcome events in a 180 patient MASH cirrhosis cohort treated with resmetirom

Poster Presentation

 DownloadPreview
Early and Week 52 biomarker (MRI-PDFF, ALT, MRE and PRO-C3) responses to resmetirom predict improvements in MASH and liver fibrosis

Poster Presentation

 DownloadPreview
In F0-F1 and F2-F3 MASH, ≥ 5% weight loss significantly lowers VCTE and ELFTM independent of biopsy fibrosis improvement; resmetirom and not placebo reduction of ELF and VCTE are associated with biopsy improvement of fibrosis, independent of weight loss

Poster Presentation

 DownloadPreview
Machine Learning Models of Non-invasive Tests to Predict MASH and Fibrosis Stage Based on MAESTRO-NAFLD-1 and MAESTRO-NASH Liver Biopsies

Poster Presentation

 DownloadPreview
Reducing CV risk in patients with MASH independent of baseline statin use: Lp(a) and LDL-C lowering by resmetirom

Poster Presentation

 DownloadPreview
Download all
  • EASL 2026 - HEOR
TitleDescriptionDownload
Twelve-month changes in liver function enzymes, lipids, and vibration-controlled transient elastography measures in patients receiving resmetirom

Poster Presentation

 DownloadPreview
Non-invasive test-driven modeling of patient eligibility for resmetirom therapy in MASLD: Data from the German SLD-Registry

Poster Presentation

 DownloadPreview
Early real-world effectiveness of resmetirom in adults with metabolic dysfunction associated steatohepatitis and moderate-to-advanced fibrosis

Poster Presentation

 DownloadPreview